NCT03546868

Diagnostic Validity of [18F]FSPG PET for the Assessment of Disease Activity in Inflammatory Bowel Disease

Phase 2, Open-label, Non-randomized, Single Center Study to Explore Diagnostic Validity of [18F]FSPG PET for the Assessment of Disease Activity in Subjects With Inflammatory Bowel Disease.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Asan Foundation · Academic / Other
• Sex: All
• Age: 19 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

Diagnostic validity of \[18F\]FSPG for assessing disease activity will be assessed in subjects with inflammatory bowel disease.

Detailed description

\[18F\]FSPG PET/CT imaging will noninvasively assess system xc- of cancer and inflammation. Diagnostic validity of \[18F\]FSPG for assessing disease activity will be assessed in subjects with inflammatory bowel disease.

Conditions

• Inflammatory Bowel Diseases
• Ulcerative Colitis
• Crohn Disease

Interventions

Type	Name	Description
DRUG	[18F]FSPG	Patients will receive 200 MBq of \[18F\]FSPG and undergo PET/CT for assessing disease activity in inflammatory bowel disease

Timeline

• Start date: 2018-08-14
• Primary completion: 2019-01-11
• Completion: 2019-01-11
• First posted: 2018-06-06
• Last updated: 2020-12-14

Locations

2 sites across 1 country: South Korea